

Non-Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line

Failed Therapy

EGFR +

Failed EFGR TKI

TKI
1st/3rd
Generation

EGFR 19
or 21

RET+

ALK +

KRAS G12
C+

MET/RET/ROS1

PTK7 + Study
Screening

LUN0123

Phase I/II Study
of the Selective
RET Inhibitor
TAS0953/HM06
in Patients with
Advanced Solid
Tumors with RET
Gene
Abnormalities

PI: Wakelee
Sponsor: Helsinn
Healthcare SA

LUN0110
(Expanded
Access)

Expanded
Access
Intermediate-
Size Patient
Population
Protocol

PI: Wakelee
Sponsor:
Xcovery

**ECOG
ACRIN-S1900-E**

Phase II AMG
510 in
Previously Tx
Stage IV or
Recurrent
KRAS G12C
Mutated
Non-Squamous
NSCLC LUNGMAP

PI: Neal
Sponsor:
ECOG-ACRIN

**ECOG-ACRIN
-EA5191**

Phase II
Cabozantinib
+/-Nivolumab vs
Standard
Chemotherapy
in Previously
Treated NSCLC

PI: Neal
Sponsor:
ECOG-ACRIN

LUN0111

Phase 1b
Cofetuzumab
Pelidotin
(ABBV-647)
in PTK7-
Expressing
Recurrent
NSCLC

PI: Neal
Sponsor:
Pending

LUN0090

Phase I
Afatinib &
Necitumumab
in EGFR
Mutation+
NSCLC w/ 1st /
3rd Gen EGFR
TKIs Acquired
Resistance

PI: Padda
Sponsor:
Vanderbilt
University

LUN0112

Phase II
Carboplatin +
Pemetrexed
+
Bevacizumab
+/-
Atezolizumab
in Stage IV
Non-
Squamous
NSCLC

PI: Wakelee
Sponsor: NCCN

LUN0122

Phase I/II
JNJ-73841937
(Lazertinib)
Monotherapy
or in Combo w/
JNJ-61186372
in Advanced
NSCLC




PI: Neal
Sponsor: Janssen
Research




THOR0006



Phase I/II
Nivolumab in
Combination
with Vorolanib
in Refractory
Thoracic
Tumors

PI: Wakelee
Sponsor: NCCN

KEY

-  Pending
-  Open for Enrollment
-  Observational Study

-  Optional Path
-  Trial Posting
-  Enrollment on Hold

-  Extension Study
-  Immunotherapy